18F-DCFBC
DRACPC ID DRACPC0054
Active Ingredients 18F-DCFBC
Description A radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the DCFBC moiety of fluorine F 18 DCFBC specifically targets and binds to the tumor associated antigen PSMA, thereby allowing the visualization of tumor cells expressing PSMA upon PET. PSMA is a transmembrane glycoprotein highly expressed on malignant prostate epithelial cells and vascular endothelial cells of various solid tumors.
Synonyms DCFBC F-18; Fluorine F 18 DCFBC; [18]F-DCFBC;N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine; 18F-DCFBC
Type Small Molecule
Disease Prostatet cancer
Classification
Peptide and derivative Cancer targeted Radioconjugates
Structure Information
Molecular Formula C16H19FN2O7S
Molecular Weight 401.4
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2S)-2-[[(1R)-1-carboxy-2-[(4-(18F)fluoranylphenyl)methylsulfanyl]ethyl]carbamoylamino]pentanedioic acid
InChI InChI=1S/C16H19FN2O7S/c17-10-3-1-9(2-4-10)7-27-8-12(15(24)25)19-16(26)18-11(14(22)23)5-6-13(20)21/h1-4,11-12H,5-8H2,(H,20,21)(H,22,23)(H,24,25)(H2,18,19,26)/t11-,12-/m0/s1/i17-1
InChI_Key IDTMSHGCAZPVLC-STUNTBJNSA-N
SMILES O=C(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CSCC1=CC=C(C=C1)[18F])=O)O
External Codes
PubChem CID 25067411
DrugBank Accession Number DB14772
NCI Thesaurus Code C96234
UNII TUP7882K8T GSRS
CAS 1169942-33-9
Drug approval
Drug indication
Investigated for use/treatment in prostatet cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT01815515 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer. | Metastatic Prostate Cancer | Phase 1/2 | Diagnostic |
| NCT01417182 | Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA Based PET in Patients With Advanced Prostate Cancer | Prostate Cancer | Phase 1 | Screening |
| NCT02190279 | A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer | Prostatic Neoplasms; Prostate Cancer | Early Phase 1 | Diagnostic |
| NCT01496157 | Evaluation of PSMA-based PET as an Imaging Biomarker of Primary Prostate Cancer | Prostate Cancer | Phase 1/2 | Diagnostic |
More clinical information is obtained from ClinicalTrials.gov.
